Harrow Reaffirms 2025 Guidance, Expands Eyecare Brands Amid Regulatory Resolutions

Harrow (HROW) reaffirmed its 2025 revenue guidance of $270-$280mln and outlined expansion plans for key eyecare brands. The company has resolved regulatory issues tied to its ImprimisRx division and its share price has seen a 10.82% 7-day return and 37.05% 90-day return. Harrow's valuation is at $47.20, with an analyst price target of $70.63, indicating an intrinsic discount. The most followed narrative pegs Harrow's fair value at $70.63, making it undervalued.